Eisai’s research subsidiary, Morphotek, a biotechnology company headquartered in Exton, Pennsylvania, has signed an exclusive licensing agreement with Eurofarma Laboratórios, a São Paulo, Brazil-based pharmaceutical company, to develop and commercialize farletuzumab, a monoclonal antibody being developed as a potential anticancer agent in Latin America.

Under the agreement, Morphotek will receive an upfront payment from Eurofarma as well as scheduled development and sales milestone payments. Additionally, Morphotek will receive royalties from commercial sales of farletuzumab in Latin America. Morphotek will supply Eurofarma with clinical and commercial materials while Eurofarma has the option to assume responsibility for filling and packaging farletuzumab vials. Morphotek retains all rights to develop and commercialize farletuzumab in regions outside of Latin America. Farletuzumab is currently in a Phase II clinical study for first-relapsed, platinum-sensitive ovarian cancer.

Source: Eisai